JGC
KYNB

J. Goldman & Co’s Kyntra Bio KYNB Stock Holding History

J. Goldman & Co’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,080
Closed -$72.9K – 394
2023
Q2 		$72.9K Buy
+1,080
New +$447K ﹤0.01% 348
2023
Q1 		– Sell
-4,548
Closed -$1.82M – 395
2022
Q4 		$1.82M Buy
+4,548
New +$1.74M 0.09% 180

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's KYNB Position: Q3 2023 in Review

J. Goldman & Co sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 1,080 shares — an estimated $72.9K sold.

J. Goldman & Co first reported a position in KYNB in Q4 2022 and held it in 2 quarters. The position peaked at $1.82M in Q4 2022. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

  • J. Goldman & Co reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
  • J. Goldman & Co sold 1,080 Kyntra Bio shares in Q3 2023, an estimated $72.9K.
  • J. Goldman & Co first reported a position in Kyntra Bio in Q4 2022 and held it in 2 quarters.
  • J. Goldman & Co's Kyntra Bio position peaked at $1.82M in Q4 2022.
  • 110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on J. Goldman & Co's 13F filing for Q3 2023, filed 14 Nov 2023.